HennVSlupskyJRGrafeMAnagnostopoulosIForsterRMuller-BerghausG. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature1998; 391: 591–4.
2.
AmirkhosraviAAmayaMDesaiHFrancisJL. Platelet-CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular procoagulant activity. Blood Coagul Fibrinolysis2002; 13: 505–12.
3.
AndrePPrasadKSDenisCV. CD40L stabilizes arterial thrombi by a beta3 integrin—dependent mechanism. Nat Med2002; 8: 247–52.
4.
InwaldDPPetersMJWalsheDJonesADaviesEGKleinNJ. Absence of platelet CD40L identifies patients with X-linked hyper IgM syndrome. Clin Exp.Immunol.2000; 120: 499–502.
5.
InwaldDPMcDowallAPetersMJCallardREKleinNJ. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ.Res.2003; 92: 1041–8.
6.
InwaldDPKirkhamFJPetersMJ. Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia. Br.J Haematol.2000; 111: 474–81.
7.
InwaldDFaustSPetersMJHeydermanRSLevinM and KleinNJ. Role of platelet CD40L in meningococcal sepsis. Fourth World Congress on Pediatric Intensive Care. Boston, MA June 8–12, 2003.
8.
Nannizzi-AlaimoLAlvesVLPhillipsDR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation2003; 107: 1123–8.